MARIETTA, Ga., Sept. 22, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, announced today the publication of the Company's Primer "Amniotic Membrane Regenerative Healing" and its unveiling at the Symposium on Advanced Wound Care (SAWC) Fall 2015 meeting in Las Vegas, Nevada from September 26th - 28th, 2015.
The MiMedx Primer is being offered to healthcare professionals to help educate and bring discipline to the development and use of the promising amniotic tissue technology. "We believe our Primer should clarify numerous issues in terms of the healing process, the modes of action of amniotic membrane allografts, and the basis for demonstrating clinical safety and efficacy for these allografts. We trust that clinicians will appreciate the education this book will provide," said Parker H. "Pete" Petit, Chairman and CEO.
Since MiMedx introduced its uniquely processed amniotic membrane allografts in 2006, there has been a steady increase in the utilization of this tissue. The use of these allografts in advanced wound care has escalated very rapidly since 2012, and its utilization in certain surgical procedures has steadily increased since 2013.
"When any new technology with significant promise escalates this rapidly, there are numerous issues that develop, particularly when the technology is complex both scientifically and clinically. The chance for misinformation and pseudoscience is heightened, and this is a disservice to the clinicians and scientists who are attempting to substantiate the attributes of the new technology," added Petit. "Amniotic membrane offers many unique qualities and possibilities to enhance healing, reduce scar tissue formation, and modulate inflammation. However, there must be a discipline associated with bringing these new products and technology into commercialization. I believe this Primer will help bring discipline to the process, and therefore, assist clinicians in making their assessments as to the attributes of these allografts which make them more clinically and cost effective than conventional therapies."
The 170 page Primer is a comprehensive textbook with discourse on the essential aspects of amniotic membrane technology. The Primer addresses the foundation of amniotic membrane technology and its tissue regeneration potential; the critical facets of the healing stimulated and elevated by amniotic membrane; the methodology, statistical relevance and approaches to conducting clinical trials on humans to systematically determine the effectiveness of therapeutic intervention; and the results produced from the abundance of clinical studies and peer-reviewed publications on MiMedx dehydrated human amnion/chorion membrane (dHACM) allografts.
Bill Taylor, President and COO, commented, "With so much potential ahead of this high growth sector of health care, someone has to set the benchmark for conducting credible research, development, clinical studies and marketing. We have earned that leadership position. The more effectively our industry sector reveals the science that is contributing to the healing potential of amniotic membrane allografts and the stricter precision that is applied to all clinical studies, the more the regenerative healing of this new amniotic membrane technology will become a standard of care."
"Our motivation in producing this Primer is to assist in conveying the scientific and clinical discipline, rigor and order that should be the on-going standard. While this technology is still emerging, we believe our offering of this comprehensive reference material will be a great benefit to the orderly acceptance and application of amniotic allografts," concluded Petit.
Throughout the three-day SAWC, MiMedx will be presenting at Booth #301.
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies are AmnioFix®, EpiFix® and CollaFix™. AmnioFix® and EpiFix® are our tissue technologies processed from human amniotic membrane derived from donated placentas. Through our donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 450,000 allografts to date for application in the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. CollaFix™, our next technology platform we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. CollaFix™ is the only biological, biodegradable, biomimetic technology that matches human tendon in strength and stiffness.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, that amniotic tissue allografts are more clinically and cost effective than conventional therapies and the Primer will assist in clinicians' assessment of amniotic tissue as such, and that amniotic membrane technology will become a standard of care. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the Primer does not adequately address all aspects of amniotic tissue allograft technology for clinicians, that amniotic tissue allografts do not gain acceptance in the medical community or do not otherwise become the standard of care, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2014 and its most recent Form 10Q filing. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
SOURCE MiMedx Group, Inc.